Journal of Cancer Research and Practice

CASE REPORT
Year
: 2019  |  Volume : 6  |  Issue : 1  |  Page : 50--54

Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer


Yi-Hsuan Lai1, Shih-Hung Yang2 
1 Division of Hematology and Oncology, Department of Internal Medicine, Taipei City Hospital, Renai Branch, Taipei, Taiwan
2 Department of Oncology; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Correspondence Address:
Dr. Shih-Hung Yang
Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002
Taiwan

Ampullary cancer is a rare type of cancer with a limited choice of systemic therapy. Anti-programmed death-1 monoclonal antibodies have shown promising clinical benefits in multiple types of cancer, especially in tumors with microsatellite instability-high (MSI-H)/defective DNA mismatch repair and high tumor mutation burden. We report a case of a 61-year-old woman with MSI-H ampullary cancer who initially had slow progression without chemotherapy after recurrence. She experienced hyperprogressive disease with a dramatic deterioration of liver metastases following a short duration of nivolumab treatment.


How to cite this article:
Lai YH, Yang SH. Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer.J Cancer Res Pract 2019;6:50-54


How to cite this URL:
Lai YH, Yang SH. Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer. J Cancer Res Pract [serial online] 2019 [cited 2022 Sep 28 ];6:50-54
Available from: https://www.ejcrp.org/article.asp?issn=2311-3006;year=2019;volume=6;issue=1;spage=50;epage=54;aulast=Lai;type=0